Evidence map›Paper›PMID 26380186›Full record

ArticleTranslational lung cancer research2015

Implementing effective and sustainable multidisciplinary clinical thoracic oncology programs.

Raymond U Osarogiagbon, Richard K Freeman, Mark J Krasna

Abstract read
In one paragraph

Article in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Raymond U Osarogiagbon1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Regional Chief Medical Officer, Vice Chairman for Surgery, St Vincent Health and Hospital System, Indianapolis, Indiana, USA ; 3 Corporate Medical Director, Meridian Cancer Care, Neptune, NJ, USA .
Richard K Freeman1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Regional Chief Medical Officer, Vice Chairman for Surgery, St Vincent Health and Hospital System, Indianapolis, Indiana, USA ; 3 Corporate Medical Director, Meridian Cancer Care, Neptune, NJ, USA .
Mark J Krasna1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Regional Chief Medical Officer, Vice Chairman for Surgery, St Vincent Health and Hospital System, Indianapolis, Indiana, USA ; 3 Corporate Medical Director, Meridian Cancer Care, Neptune, NJ, USA .

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three models of care are described, including two models of multidisciplinary care for thoracic malignancies. The pros and cons of each model are discussed, the evidence supporting each is reviewed, and the need for more (and better) research into care delivery models is highlighted. Key stakeholders in thoracic oncology care delivery outcomes are identified, and the need to consider stakeholder perspectives in designing, validating and implementing multidisciplinary programs as a vehicle for quality improvement in thoracic oncology is emphasized. The importance of reconciling stakeholder perspectives, and identify meaningful stakeholder-relevant benchmarks is also emphasized. Metrics for measuring program implementation and overall success are proposed.

Indexed as

benchmarkshealth service researchlung cancermodel of care deliveryQuality of care

Identifiers

PMID26380186
PMCPMC4549478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.